These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12654737)

  • 1. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.
    Stiegler G; Katinger H
    J Antimicrob Chemother; 2003 Apr; 51(4):757-9. PubMed ID: 12654737
    [No Abstract]   [Full Text] [Related]  

  • 2. Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice.
    Koup RA; Safrit JT; Weir R; Gauduin MC
    Semin Immunol; 1996 Aug; 8(4):263-8. PubMed ID: 8883150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
    Trkola A; Kuster H; Rusert P; Joos B; Fischer M; Leemann C; Manrique A; Huber M; Rehr M; Oxenius A; Weber R; Stiegler G; Vcelar B; Katinger H; Aceto L; Günthard HF
    Nat Med; 2005 Jun; 11(6):615-22. PubMed ID: 15880120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies take a swipe at HIV in vivo.
    Montefiori DC
    Nat Med; 2005 Jun; 11(6):593-4. PubMed ID: 15937465
    [No Abstract]   [Full Text] [Related]  

  • 5. Passive immunization for the treatment of HIV infection.
    Jacobson JM
    Mt Sinai J Med; 1998 Jan; 65(1):22-6. PubMed ID: 9458680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive immunization for the treatment and prevention of HIV infection.
    Karwowska S; Zolla-Pazner S
    Biotechnol Ther; 1991; 2(1-2):31-48. PubMed ID: 1845123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
    Jülg B; Goebel FD
    Infection; 2005 Oct; 33(5-6):405-7. PubMed ID: 16258878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.
    Steyaert S; Heyndrickx L; Verhoye L; Vermoesen T; Donners H; Fransen K; Van Wanzeele F; Vandergucht B; Vanham G; Leroux-Roels G; Vanlandschoot P
    Antiviral Res; 2007 Aug; 75(2):129-38. PubMed ID: 17379323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive immunization with HIV-1-neutralizing antibodies: is it effective and safe?
    Nittayananta W
    Oral Dis; 2016 Sep; 22(6):460-2. PubMed ID: 27009613
    [No Abstract]   [Full Text] [Related]  

  • 12. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
    Jaworski JP; Cahn P
    Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HIV-1 cell-to-cell transmission and broadly neutralizing antibodies].
    Malbec M; Mouquet H; Schwartz O
    Med Sci (Paris); 2014 May; 30(5):508-10. PubMed ID: 24939535
    [No Abstract]   [Full Text] [Related]  

  • 14. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody.
    Verity EE; Williams LA; Haddad DN; Choy V; O'Loughlin C; Chatfield C; Saksena NK; Cunningham A; Gelder F; McPhee DA
    AIDS; 2006 Feb; 20(4):505-15. PubMed ID: 16470114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human monoclonal antibodies for passive immunotherapy of HIV-1.
    Katinger H
    Antibiot Chemother (1971); 1994; 46():25-37. PubMed ID: 7826037
    [No Abstract]   [Full Text] [Related]  

  • 16. Broadly neutralizing antibodies: An approach to control HIV-1 infection.
    Yaseen MM; Yaseen MM; Alqudah MA
    Int Rev Immunol; 2017 Jan; 36(1):31-40. PubMed ID: 27739924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aids: results with antibodies questionable].
    Paris KA
    Fortschr Med; 1992 Jun; 110(18):16. PubMed ID: 1644392
    [No Abstract]   [Full Text] [Related]  

  • 19. The membranes' role in the HIV-1 neutralizing monoclonal antibody 2F5 mode of action needs re-evaluation.
    Veiga AS; Castanho MA
    Antiviral Res; 2006 Aug; 71(1):69-72. PubMed ID: 16530275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of neutralizing antibodies against Ebola virus infection.
    Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
    Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.